[1]曾谷雨 袁晋青.慢性冠状动脉综合征二级预防的抗血小板及抗凝治疗研究进展[J].心血管病学进展,2021,(12):1061-1063,1073.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
　ZENG Guyu,YUAN Jingqing.Antiplatelet and Antithrombotic Therapy for the Secondary Prevention of Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(12):1061-1063,1073.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
点击复制

慢性冠状动脉综合征二级预防的抗血小板及抗凝治疗研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年12期
页码:
1061-1063,1073
栏目:
综述
出版日期:
2021-12-25

文章信息/Info

Title:
Antiplatelet and Antithrombotic Therapy for the Secondary Prevention of Chronic Coronary Syndrome
作者:
曾谷雨 袁晋青
(中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院,北京 100037)
Author(s):
ZENG Guyu; YUAN Jingqing
(Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100037,China)
关键词:
慢性冠状动脉综合征; 抗血小板药物; 抗凝药物; 二级预防
Keywords:
Chronic coronary syndrome; Antiplatelet drugs; Antithrombotic drugs; Secondary prevention
DOI:
10.16806/j.cnki.issn.1004-3934.2021.12.002
摘要:
阿司匹林是慢性冠状动脉综合征患者抗血小板治疗的基石，但由于患者服用阿司匹林后仍有发生缺血事件的风险，寻找新的二级预防手段成为了近年来的热点。随着新型P2Y12受体拮抗剂和新型口服抗凝药的出现，近期与之相关的临床试验为慢性冠状动脉综合征患者的二级预防提供了新的循证医学证据。现拟对慢性冠状动脉综合征二级预防抗血小板和抗凝治疗的进展做一综述。
Abstract:
Aspirin is the cornerstone of antiplatelet therapy in the secondary prevention of chronic coronary syndrome (CCS). However,the high risk of recurrent ischemic events threats the role of single aspirin therapy,and scientists attempt to find new strategies superior to aspirin for the patients with CCS. Recently,some large clinical trials showed efficacy of new P2Y12 antagonists and new oral anticoagulants in the secondary prevention of CCS. Therefore ,we try to summarize recent evidences of new strategies for the secondary prevention of CCS,especially the part related to antiplatelet drugs and antithrombotic drugs.


参考文献/References:

[1] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)[J]. Eur Heart J,2020,41(3):407-477.
[2] Bhatt DL,Eagle KA,Ohman EM,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis[J]. JAMA,2010,304(12):1350-1357.
[3] Anand SS,Yusuf S. Oral anticoagulants in patients with coronary artery disease[J]. J Am Coll Cardiol,2003,41(4 suppl S):62s-69s.
[4] Anand SS,Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis[J]. JAMA,1999,282(21):2058-2067.
[5] Mega JL,Braunwald E,Wiviott SD,et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med,2012,366(1):9-19.
[6] Eikelboom JW, Connolly SJ, Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.
[7] CAPRIE Steering Committee.A randomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee[J]. Lancet,1996,348(9038):1329-1339.
[8] Bhatt DL,Fox KA,Hacke W,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events[J]. N Engl J Med,2006,354(16):1706-1717.
[9] Bhatt DL,Flather MD,Hacke W,et al. Patients with prior myocardial infarction,stroke,or symptomatic peripheral arterial disease in the CHARISMA trial[J]. J Am Coll Cardiol,2007,49(19):1982-1988.
[10] Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057.
[11] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800.
[12] Bhatt DL,Bonaca MP,Bansilal S,et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54[J]. J Am Coll Cadiol,2016,67(23):2732-2740.
[13] Bansilal S,Bonaca MP,Cornel JH,et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease[J]. J Am Coll Cardiol,2018,71(5):489-496.
[14] Bonaca MP,Bhatt DL,Storey RF,et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease[J]. J Am Coll Cardiol,2016,67(23):2719-2728.
[15] Steg PG,Bhatt DL,Simon T,et al. Ticagrelor in patients with stable coronary disease and diabetes[J]. N Engl J Med,2019,381(14):1309-1320.

相似文献/References:

[1]张鹏 刘东升 张俊峰.血小板活化相关信号转导机制研究进展[J].心血管病学进展,2020,(10):1078.[doi:10.16806/j.cnki.issn.1004-3934.20.10.019]
　ZHANG Peng,LIU Dongsheng,ZHANG Junfeng.Signal Transduction Mechanism Related to Platelet Activation[J].Advances in Cardiovascular Diseases,2020,(12):1078.[doi:10.16806/j.cnki.issn.1004-3934.20.10.019]
[2]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
　SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(12):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]

更新日期/Last Update: 2022-01-07